As at 2 march 2026, the sunflower industry (002,737) had received 13. 74 yuan, a decrease of 2. 07 per cent, a change of hands rate of 0. 7 per cent, a deal of 411,000, and a deal of $56,746. 5 million。
Focus on the day transaction information aggregates the financial flows
On 2 march, there was a net outflow of primary resources of $3. 735 million; a net inflow of travel funds of $1,23. 19 million; and a net inflow of bulk funds of $2. 538 million。
The company's bulletin contains a summary of the decisions of the board of trustees at its seventeenth session
On 2 march 2026, sunflower pharmaceuticals group inc. Convened the seventeenth meeting of the fifth board of directors to consider the adoption of a proposal to elect ms. Guanichi as vice-president of the fifth board of directors of the company until the end of the current session. At the same time, consideration is being given to the adoption of the 2026 bill on the prognosis of daily associated transactions, in which companies and subsidiaries intend to engage in day-to-day related transactions with sunflower group ltd., glory (no tin) nutrition technology ltd., and harbin changstar plastics ltd. For a total amount not expected to exceed $156. 15 million, and the associated transaction pricing is based on the principle of fair market prices. Associated directors have abstained from voting on the bill。
Announcement on the election of the vice-president of the fifth board
On 2 march 2026, sunflower pharmaceuticals group inc. Convened the seventeenth meeting of the fifth board of directors to consider the proposal to elect ms. Guanichi as vice-chairman of the fifth board of directors of the company. Ms. Guan yi is currently a member of the board of directors from the date of the board's consideration and adoption until the end of the current session. Ms. Guanichi has a father-daughter relationship with the company, which effectively controls him, and is sister-in-law with the chairman of the board. There are no cases of exclusion from directorship under the companies act and there are no relevant administrative penalties or regulatory measures。
Bulletin on projected daily related transactions for 2026
The sunflower pharmaceuticals group inc. Is expected to engage in day-to-day transactions in 2026 with sunflower group ltd., glory (no tin) nutrition technology ltd. And harbin regular plastics ltd. For a total of not more than $156. 15 million. The transaction consists of authorizing the licensing of intellectual property rights, the procurement of rice and alcohol products, high health products, electricity and the sale of high health products, the pricing of which follows the principles of market equity. The matter had been considered and adopted by the board, and the independent directors had expressed their agreement that it would not need to be submitted to the general meeting of shareholders。
The above elements, which are publicly available information, are generated by ai algorithms (cylindrical code 310104345710301240019) and do not constitute an investment proposal。
